依那普利联合氯沙坦治疗老年肾性高血压的临床观察  

Clinical Observation of Enalapril Combined with Losartan on Treatment of Elderly Renal Hypertension

作　　者：徐薇 侯明英 谢怀益 陈敏 

机构地区：[1]重庆市永川区人民医院内三科,重庆402160

出　　处：《现代生物医学进展》2012年第27期5344-5346,5332,共4页Progress in Modern Biomedicine

摘　　要：目的:探讨依那普利联合氯沙坦治疗老年肾性高血压的效果。方法:选取2008年2月～2011年10月我院收治的肾性高血压患者70例,按随机数字表法分为观察组和对照组,每组35例。对照组给予依那普利20mg,每天2次;观察组给予依那普利10mg,每天2次;氯沙坦50mg,每天1次。观察两组血压、肾功能指标变化及不良反应。结果:观察组总有效率为95.0%(38/35),对照组为75.0%(30/35),差异有统计学意义(P<0.05);治疗后两组血压(DBP、SBP)和肾功能(SCr、BUN、mAlb)指标均明显改善(P<0.05),观察组较对照组改善更为明显(P<0.05);观察组不良反应发生为17.14%(6/35),对照组为14.29%(5/35),差异无统计学意义(P>0.05)。结论:依那普利联合氯沙坦治疗老年肾性高血压能更有效改善血压和肾功能,安全性高。Objective： To investigate the effect of enalapril combined with losartan on treatment of elderly renal hypertension. Methods： 70 cases of patients with renal hypertension from February 2008 to October 2011 in our hospital were selected, according to the random number table were divided into the observation group and the control group with 35 cases in each groups. The control group were given enalapril 20mg, 2 times a day; the observation group was given enalapril 10mg, twice a day; losartan 50mg, once a day. The blood pressure and renal function changes, and adverse reactions of two groups were observed. Results： The total effective rate of observation group was 95.0% （38/35）, in the control group was 75.0% （30/35）, the difference was statistically significant （P〈0.05）; blood pressure （DBP, and SBP） and renal function （SCr and BUN, mAlb） indicators were significantly improved of two groups （P〈0.05）, compared wih the control group, the observation group improved more significantly （P〈0.05）; The occurrence of adverse reactions in the observation group was 17.14% （6/35）, in the control group was 14.29% （5/35）, the difference was not statistically significant （P〉0.05）. Conclusion： Enalapril combined with losartan on treatment of elderly renal hypertension can be more effective in improving blood pressure and renal function,and has a high security.

关 键 词：氯沙坦 依那普利 肾性高血压 

分 类 号：R544.14[医药卫生—心血管疾病]